Thomas DesRosier, EVP and Chief Legal Officer of Seres Therapeutics, Inc., filed a Form 4 on November 17, 2026, disclosing transactions in common stock and restricted stock units on November 15 and 16, 2026.
Key Highlights
- RSU conversions: DesRosier acquired 244 shares of common stock on November 15, 2026, via two RSU vestings coded as transaction type "M."
- Sale to cover taxes: 103 shares were sold on November 16, 2026, at $1.38 per share, pursuant to a Rule 10b5-1 instruction adopted March 2, 2023, solely to cover taxes related to RSU vesting.
- Remaining beneficial ownership: Following the transactions, DesRosier directly owned 8,258 shares of common stock.
- RSU balances: After the vestings, DesRosier held 132 RSUs from one grant and 556 RSUs from a second grant, for a total of 688 remaining RSUs.
- Issuer and exchange: Seres Therapeutics, Inc. trades under ticker MCRB, listed as NASDAQ:MCRB in the filing.
DesRosier RSU Vesting and Tax-Related Sale at Seres Therapeutics
According to the filing, Thomas DesRosier, in his role as EVP and Chief Legal Officer of Seres Therapeutics, Inc. (NASDAQ:MCRB), reported two separate RSU-related acquisitions of common stock on November 15, 2026. One restricted stock unit grant contributed 133 shares and a second contributed 111 shares, together totaling 244 shares acquired, bringing his directly held common stock position to 8,361 shares at that point. The filing notes that each restricted stock unit represents a contingent right to receive one share of issuer common stock, and that both RSU grants carried a derivative security price of $0.
On November 16, 2026, DesRosier disposed of 103 shares at a price of $1.38 per share. The filing states that the sale "was effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units." Following this sale, his directly held common stock position stood at 8,258 shares.
Regarding the two RSU grants, the filing explains that the first grant vested and settled as to 25% on February 15, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, and carries no expiration date. The second grant vested and settled as to 25% on February 15, 2025, also with subsequent quarterly installments and no expiration date. After the November 15, 2026 vestings, DesRosier retained 132 RSUs from the first grant and 556 RSUs from the second grant, all held directly.
What Was Disclosed
The Form 4 discloses RSU vestings totaling 244 shares on November 15, 2026, and a Rule 10b5-1 plan sale of 103 shares at $1.38 on November 16, 2026, by EVP and Chief Legal Officer Thomas DesRosier, leaving him with 8,258 directly held shares.



Please wait processing your request...